Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine

Patient

1

2

3

4

5

Age (years)

61

36

55

38

40

Sex

F

M

M

M

M

Race

Asian

Asian

Asian

Asian

Asian

Diagnosis

CHB

CHB

HBV-related cirrhosis, HCC

CHB

CHB

HBV genotype

C

C

C

C

C

HBeAg/Anti-HBe

−/+

+/−

+/−

+/−

+/−

Antiviral treatment history (months)

ADV (36)

a

LAM (12)

ADV (36)

LAM (12)

ADV (12)

LAM (12)

ADV (12)

LAM+ADV (8)

LAM (36)

LAM+ADV (8)

LdT (6)

Results of sequencing

rtM204 V+rtL180 M+rtA181 V

rtM204 V+rtL180 M+rtA181 V

rtM204 V+rtL180 M+rtA181 V

rtM204 I+rtA181 V/T

rtM204 V+rtL180 M+rtA181 V

  1. ADV adefovir dipivoxil, LAM lamivudine, LdT telbivudine, PCR polymerase chain reaction, CHB chronic hepatitis B, HCC hepatocellular carcinoma, LAM + ADV LAM and ADV combination therapy
  2. a↓ indicates followed by